N Engl J Med 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
ABSTRACT
BACKGROUND
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor () mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.
METHODS
In this double-blind, phase 3 trial, we randomly assigned patients with completely resected mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years. The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment). The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety.
RESULTS
A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group). At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% confidence interval [CI], 84 to 93) and 44% of those in the placebo group (95% CI, 37 to 51) were alive and disease-free (overall hazard ratio for disease recurrence or death, 0.17; 99.06% CI, 0.11 to 0.26; P<0.001). In the overall population, 89% of the patients in the osimertinib group (95% CI, 85 to 92) and 52% of those in the placebo group (95% CI, 46 to 58) were alive and disease-free at 24 months (overall hazard ratio for disease recurrence or death, 0.20; 99.12% CI, 0.14 to 0.30; P<0.001). At 24 months, 98% of the patients in the osimertinib group (95% CI, 95 to 99) and 85% of those in the placebo group (95% CI, 80 to 89) were alive and did not have central nervous system disease (overall hazard ratio for disease recurrence or death, 0.18; 95% CI, 0.10 to 0.33). Overall survival data were immature; 29 patients died (9 in the osimertinib group and 20 in the placebo group). No new safety concerns were noted.
CONCLUSIONS
In patients with stage IB to IIIA mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
Related Questions
New answer by Medical Oncologist at Wexner Medical Center at The Ohio State University (November 24, 2020)
Giant cell carcinomas/pleomorphic carcinomas/sarcomatoid carcinomas are difficult, and typically aggressive entities. In reviewing the literature, there is precious little dat...
Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?
New answer by Medical Oncologist at Yale Cancer Center At Smilow Cancer Hospital (February 8, 2021)
I will continue to use chemotherapy in the adjuvant setting in stage 2 and 3 disease, as that has shown a clear survival benefit.
What was the magnitude of benefit for patients with EGFRm NSCLC by stage?
Are you still considering adjuvant osimertinib for patients with earl...
New answer by Medical Oncologist at University of Virginia (March 5, 2021)
I agree with the previous comments and would offer to stage IB as well with the caveat that the likelihood of benefit may be smaller than the more advanced stage. It is worth ...
New answer by Medical Oncologist at Roswell Park Comprehensive Cancer Center (March 9, 2021)
In the ADAURA trial, non-adenocarcinoma histology comprised < 5% of cases, which reflects the well-known distribution of sensitizing EGFR mutations which is largely found i...
New answer by Medical Oncologist at Karmanos Cancer Institute (March 16, 2021)
ADAURA trial was not designed to address this issue. But that being said, we need to remember few things before considering "maintenance durvalumab" in patients with...
Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?
New comment by Radiation Oncologist at Mon Health ( March 16, 2021)
Thank you. Stay safe, my friend.
-Fred
Can adjuvant durvalumab or other I/O or osimertinib (if EGFR+) be considered?
New comment by Medical Oncologist at Intermountain Healthcare ( August 6, 2021)
Curious about your observation that paclitaxel/gem is better tolerated as a 2nd drug than pemetrexed, as that has not been my observation. What dosing of paclitaxel are you us...
New answer by Medical Oncologist at Indiana University School of Medicine (October 15, 2021)
Probably not. The cure rate for stage IA adenocarcinoma is 75-90%, depending on the details (including size). The ADAURA trial demonstrated a substantially improved DFS favori...
New answer by Medical Oncologist at University of Illinois College of Medicine at Chicago (December 31, 2021)
We perform next generation sequencing and PD-L1 testing on all lung cancer patients regardless of stage or histology.